Glatiramer acetate long acting injection - Consegna Pharma
Alternative Names: CP-116; Glatiramer acetate long acting injection - Consegna PharmaLatest Information Update: 30 Apr 2026
At a glance
- Originator Consegna Pharma
- Class Antipsychotics; Behavioural disorder therapies; Peptides; Polymers
- Mechanism of Action Immunomodulators; MHC class II gene modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase Unknown Psychiatric disorders
Most Recent Events
- 27 Apr 2026 Glatiramer long acting injection is available for licensing as of 27 Apr 2026. https://www.consegnapharma.com/pipeline (Consegna Pharma website, April 2026)
- 27 Apr 2026 Investigation in Psychiatric disorders in USA (Parenteral), before April 2026 (Consegna Pharma pipeline, April 2026)